CTOs on the Move

Concuity

www.concuity.com

 
Concuity is a Vernon Hills, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.concuity.com
  • 200 N Fairway Dr Ste 182
    Vernon Hills, IL USA 60061
  • Phone: 847.465.6003

Executives

Name Title Contact Details

Similar Companies

BlossomHill Therapeutics

BlossomHill Therapeutics is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders.

Exosome Diagnostics

Exosome Diagnostics is developing biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are shed into all biofluids, including blood, urine and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company`s proprietary exosome technology makes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases.

Southern Research Institute

Southern Research Institute is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Healthsouth Rehabilitation Hospital

Healthsouth Rehabilitation Hospital is a Las Vegas, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

RAPT Therapeutics

RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the company develops highly selective small molecules that are designed to modulate the fundamental immune responses underlying these diseases. RAPT has rapidly discovered and advanced two unique drug candidates each targeting CCR4, including our lead oncology drug candidate, FLX475, now in clinical development and our lead inflammation drug candidate, RPT193, expected to enter the clinic in the second half of 2019. The company is also pursuing other discovery targets including GCN2 and HPK1 for the treatment of cancer.